In this article

LLY

Follow your favorite stocks CREATE FREE ACCOUNT

Eli Lilly on Thursday said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study.

The highest dose of the weekly injection, called eloralintide, helped patients with obesity or who are overweight lose 20.1% of their body weight on average at 48 weeks. The results support the pharmaceutical giant's efforts to bring next-generation treatments to the blockbuster weight loss drug market, and solidify its dominance in the segment.

The data bolsters Eli Lilly's chances of bringing a strong competitor to the red-hot amylin space, in particular. Many industry analysts view so-called amylin analogs as the next wave of obesity tr

See Full Page